REGN Intrinsic Valuation and Fundamental Analysis - Regeneron Pharmaceuticals Inc - Alpha Spread

Regeneron Pharmaceuticals Inc
NASDAQ:REGN

Watchlist Manager
Regeneron Pharmaceuticals Inc Logo
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Watchlist
Price: 1 015.67 USD 1.67% Market Closed
Market Cap: 112B USD
Have any thoughts about
Regeneron Pharmaceuticals Inc?
Write Note

Intrinsic Value

The intrinsic value of one REGN stock under the Base Case scenario is 562.25 USD. Compared to the current market price of 1 015.67 USD, Regeneron Pharmaceuticals Inc is Overvalued by 45%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

REGN Intrinsic Value
562.25 USD
Overvaluation 45%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Regeneron Pharmaceuticals Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for REGN cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about REGN?
Bearish
Neutral
Bullish

Fundamental Analysis

Summary

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

AI Assistant
AI Assistant
Ask me anything about Regeneron Pharmaceuticals Inc

Provide an overview of the primary business activities
of Regeneron Pharmaceuticals Inc.

What unique competitive advantages
does Regeneron Pharmaceuticals Inc hold over its rivals?

What risks and challenges
does Regeneron Pharmaceuticals Inc face in the near future?

Has there been any significant insider trading activity
in Regeneron Pharmaceuticals Inc recently?

Summarize the latest earnings call
of Regeneron Pharmaceuticals Inc.

What significant events have occurred
in Regeneron Pharmaceuticals Inc over the past months?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Regeneron Pharmaceuticals Inc.

Provide P/S
for Regeneron Pharmaceuticals Inc.

Provide P/E
for Regeneron Pharmaceuticals Inc.

Provide P/OCF
for Regeneron Pharmaceuticals Inc.

Provide P/FCFE
for Regeneron Pharmaceuticals Inc.

Provide P/B
for Regeneron Pharmaceuticals Inc.

Provide EV/S
for Regeneron Pharmaceuticals Inc.

Provide EV/GP
for Regeneron Pharmaceuticals Inc.

Provide EV/EBITDA
for Regeneron Pharmaceuticals Inc.

Provide EV/EBIT
for Regeneron Pharmaceuticals Inc.

Provide EV/OCF
for Regeneron Pharmaceuticals Inc.

Provide EV/FCFF
for Regeneron Pharmaceuticals Inc.

Provide EV/IC
for Regeneron Pharmaceuticals Inc.

Show me price targets
for Regeneron Pharmaceuticals Inc made by professional analysts.

What are the Revenue projections
for Regeneron Pharmaceuticals Inc?

How accurate were the past Revenue estimates
for Regeneron Pharmaceuticals Inc?

What are the Net Income projections
for Regeneron Pharmaceuticals Inc?

How accurate were the past Net Income estimates
for Regeneron Pharmaceuticals Inc?

What are the EPS projections
for Regeneron Pharmaceuticals Inc?

How accurate were the past EPS estimates
for Regeneron Pharmaceuticals Inc?

What are the EBIT projections
for Regeneron Pharmaceuticals Inc?

How accurate were the past EBIT estimates
for Regeneron Pharmaceuticals Inc?

Compare the revenue forecasts
for Regeneron Pharmaceuticals Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Regeneron Pharmaceuticals Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Regeneron Pharmaceuticals Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Regeneron Pharmaceuticals Inc compared to its peers.

Compare the P/E ratios
of Regeneron Pharmaceuticals Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Regeneron Pharmaceuticals Inc with its peers.

Analyze the financial leverage
of Regeneron Pharmaceuticals Inc compared to its main competitors.

Show all profitability ratios
for Regeneron Pharmaceuticals Inc.

Provide ROE
for Regeneron Pharmaceuticals Inc.

Provide ROA
for Regeneron Pharmaceuticals Inc.

Provide ROIC
for Regeneron Pharmaceuticals Inc.

Provide ROCE
for Regeneron Pharmaceuticals Inc.

Provide Gross Margin
for Regeneron Pharmaceuticals Inc.

Provide Operating Margin
for Regeneron Pharmaceuticals Inc.

Provide Net Margin
for Regeneron Pharmaceuticals Inc.

Provide FCF Margin
for Regeneron Pharmaceuticals Inc.

Show all solvency ratios
for Regeneron Pharmaceuticals Inc.

Provide D/E Ratio
for Regeneron Pharmaceuticals Inc.

Provide D/A Ratio
for Regeneron Pharmaceuticals Inc.

Provide Interest Coverage Ratio
for Regeneron Pharmaceuticals Inc.

Provide Altman Z-Score Ratio
for Regeneron Pharmaceuticals Inc.

Provide Quick Ratio
for Regeneron Pharmaceuticals Inc.

Provide Current Ratio
for Regeneron Pharmaceuticals Inc.

Provide Cash Ratio
for Regeneron Pharmaceuticals Inc.

What is the historical Revenue growth
over the last 5 years for Regeneron Pharmaceuticals Inc?

What is the historical Net Income growth
over the last 5 years for Regeneron Pharmaceuticals Inc?

What is the current Free Cash Flow
of Regeneron Pharmaceuticals Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Regeneron Pharmaceuticals Inc.

Business Breakdown

Regeneron Pharmaceuticals Inc., based in Tarrytown, New York, has established itself as a powerhouse in the biopharmaceutical industry, primarily focusing on the development of innovative treatments for serious medical conditions. Founded in 1988, the company has built a robust pipeline of cutting-edge drugs that address a variety of diseases, including eye disorders, cancer, and autoimmune diseases. Regeneron's flagship product, Eylea, has transformed the treatment of retinal diseases, generating significant revenue and proving the company's capability to bring breakthrough therapies to market. The company's strong commitment to research and development is complemented by its proprietary Ve...

Read More
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Regeneron Pharmaceuticals Inc

Current Assets 19.1B
Cash & Short-Term Investments 9.8B
Receivables 5.7B
Other Current Assets 3.6B
Non-Current Assets 17B
Long-Term Investments 7.7B
PP&E 4.3B
Intangibles 1.1B
Other Non-Current Assets 3.9B
Current Liabilities 3.5B
Accounts Payable 561.7m
Accrued Liabilities 2.4B
Other Current Liabilities 586m
Non-Current Liabilities 4.4B
Long-Term Debt 2.7B
Other Non-Current Liabilities 1.7B
Efficiency

Earnings Waterfall
Regeneron Pharmaceuticals Inc

Revenue
13.5B USD
Cost of Revenue
-1.8B USD
Gross Profit
11.7B USD
Operating Expenses
-7.5B USD
Operating Income
4.2B USD
Other Expenses
123.6m USD
Net Income
4.3B USD

Free Cash Flow Analysis
Regeneron Pharmaceuticals Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

Regeneron delivered a strong Q2 2024 with a 12% rise in total revenues to $3.5 billion, driven by robust sales of EYLEA HD and its continued success globally. Earnings per share grew 13% to $11.56, indicating healthy profitability. The company saw significant growth in its collaboration with Sanofi, particularly through DUPIXENT, which showed a 29% revenue increase. Additionally, LIBTAYO sales surged by 43% due to strong demand in oncology. Regeneron's pipeline remains promising with upcoming Phase III trials and regulatory decisions. The firm expects continued revenue growth and maintained its gross margin guidance at 89% for 2024.

What is Earnings Call?
Fundamental Scores

REGN Profitability Score
Profitability Due Diligence

Regeneron Pharmaceuticals Inc's profitability score is 69/100. The higher the profitability score, the more profitable the company is.

Positive Free Cash Flow
Positive Gross Profit
Exceptional 3-Year Average ROE
Exceptional 3-Year Average ROIC
69/100
Profitability
Score

Regeneron Pharmaceuticals Inc's profitability score is 69/100. The higher the profitability score, the more profitable the company is.

REGN Solvency Score
Solvency Due Diligence

Regeneron Pharmaceuticals Inc's solvency score is 86/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Low D/E
86/100
Solvency
Score

Regeneron Pharmaceuticals Inc's solvency score is 86/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

REGN Price Targets Summary
Regeneron Pharmaceuticals Inc

Wall Street analysts forecast REGN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for REGN is 1 194.88 USD with a low forecast of 813.05 USD and a high forecast of 1 365 USD.

Lowest
Price Target
813.05 USD
20% Downside
Average
Price Target
1 194.88 USD
18% Upside
Highest
Price Target
1 365 USD
34% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for REGN?

Click here to dive deeper.

Dividends

Regeneron Pharmaceuticals Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for REGN is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

REGN Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

REGN News

Other Videos

Profile

Regeneron Pharmaceuticals Inc Logo
Regeneron Pharmaceuticals Inc

Country

United States of America

Industry

Biotechnology

Market Cap

112.8B USD

Dividend Yield

0%

Description

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. The company is headquartered in Tarrytown, New York and currently employs 10,368 full-time employees. Its commercialized medicines and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases, and rare diseases. The firm's marketed products include EYLEA (aflibercept) Injection, Dupixent (dupilumab) Injection, Libtayo (cemiplimab) Injection, Praluent (alirocumab) Injection, REGEN-COV, Kevzara (sarilumab) Solution for Subcutaneous Injection, Evkeeza (evinacumab) Injection, Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. Its product candidates in clinical development include REGN4018, REGN5668, and Fasinumab, among others.

Contact

NEW YORK
Tarrytown
777 Old Saw Mill River Rd
+19148477000.0
www.regeneron.com

IPO

1991-04-02

Employees

10 368

Officers

See Also

Discover More
What is the Intrinsic Value of one REGN stock?

The intrinsic value of one REGN stock under the Base Case scenario is 562.25 USD.

Is REGN stock undervalued or overvalued?

Compared to the current market price of 1 015.67 USD, Regeneron Pharmaceuticals Inc is Overvalued by 45%.

Back to Top